07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Notch 1 (NOTCH1); estrogen receptor-b In vitro and mouse studies suggest estrogen receptor-b agonists could help treat squamous cell carcinoma (SCC). In an analysis...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Bionovo, IP Shakti LLC endocrine/metabolic, cancer news

Menerba, an estrogen receptor beta selective agonist, was in Phase III testing to treat hot flashes in postmenopausal women, but the company could not secure funding for the trial. Bezielle is an aqueous extract from...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Clinical News

Menerba: Phase III ongoing

An independent DSMB recommended continuation of the double-blind, placebo-controlled U.S. Phase III MF101-004 trial based on safety data from 66 patients who received Menerba for >=30 days. Last month, Bionovo halted enrollment in the trial...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Company News

Bionovo endocrine/metabolic news

Bionovo reduced headcount by over 90% to save cash. At Feb. 27, the company had 52 full-time employees. The remaining management said it will cease operations if sufficient funds are not received or if the...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Financial News

Bionovo proposes private placement of common stock and warrants

Bionovo Inc. (Pink:BNVI), Emeryville, Calif.   Business: Endocrine/Metabolic, Cancer   Date announced: 3/12/12   Type: Private placement of common stock and warrants   To be raised: About $426,951   Shares: 14.2 million   Price prior:...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Company News

Bionovo endocrine/metabolic news

Bionovo retained Cowen and Co. to explore strategic options due to a lack of cash needed to meet its near term needs, including the completion of a Phase III trial with Menerba to treat menopausal...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Financial News

Bionovo proposes private placement of convertible preferred stock and warrants

Bionovo Inc. (Pink:BNVI), Emeryville, Calif.   Business: Endocrine/Metabolic, Cancer   Date announced: 2/8/12   Type: Private placement of convertible preferred stock and warrants   To be raised: Up to $25 million   Price prior: $0.13...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Financial News

Bionovo financial update

Bionovo said it will voluntarily delist its shares from NASDAQ, effective Feb. 17. The company said it would be unable to regain compliance with the $1 minimum bid price requirement for continued listing and plans...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

Bionovo management update

Bionovo Inc. (NASDAQ:BNVI), Emeryville, Calif.   Business: Endocrine/Metabolic, Cancer   Hired: David Boyle as SVP and CFO, formerly SVP and CFO of AVI BioPharma Inc.  ...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Financial News

Bionovo financial update

Bionovo entered into a two-year securities purchase agreement for up to $5 million with Socius CG II Ltd. Bionovo Inc. (NASDAQ:BNVI), Emeryville, Calif.   Business: Endocrine/Metabolic, Cancer   Date announced: 1/3/12  ...